Arjuna Capital boosted its holdings in shares of Sanofi (NASDAQ:SNY) by 45.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,504 shares of the company’s stock after purchasing an additional 2,027 shares during the period. Arjuna Capital’s holdings in Sanofi were worth $343,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in SNY. Knowledge Leaders Capital LLC increased its stake in shares of Sanofi by 1.2% in the 2nd quarter. Knowledge Leaders Capital LLC now owns 16,434 shares of the company’s stock valued at $865,000 after buying an additional 198 shares during the period. Ingalls & Snyder LLC increased its stake in shares of Sanofi by 2.2% in the 2nd quarter. Ingalls & Snyder LLC now owns 9,345 shares of the company’s stock valued at $492,000 after buying an additional 200 shares during the period. Raymond James Trust N.A. increased its stake in shares of Sanofi by 1.1% in the 2nd quarter. Raymond James Trust N.A. now owns 18,691 shares of the company’s stock valued at $984,000 after buying an additional 203 shares during the period. Clarius Group LLC increased its stake in shares of Sanofi by 3.7% in the 2nd quarter. Clarius Group LLC now owns 5,948 shares of the company’s stock valued at $313,000 after buying an additional 211 shares during the period. Finally, Meridian Wealth Partners LLC increased its stake in shares of Sanofi by 46.6% in the 1st quarter. Meridian Wealth Partners LLC now owns 777 shares of the company’s stock valued at $39,000 after buying an additional 247 shares during the period. 8.02% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:SNY traded up $0.33 during midday trading on Thursday, hitting $48.81. The company had a trading volume of 4,768 shares, compared to its average volume of 2,002,410. Sanofi has a 12 month low of $44.76 and a 12 month high of $54.26. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.28. The stock has a market cap of $123.08 billion, a price-to-earnings ratio of 17.73, a PEG ratio of 1.38 and a beta of 0.56. The firm has a fifty day simple moving average of $50.99 and a 200 day simple moving average of $51.31.
SNY has been the subject of several research reports. UBS Group reissued a “buy” rating on shares of Sanofi in a research note on Thursday, August 12th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Sanofi in a research note on Friday, July 30th. Finally, Morgan Stanley restated an “overweight” rating on shares of Sanofi in a research report on Friday, August 6th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $53.00.
In other Sanofi news, major shareholder Sanofi bought 66,667 shares of Sanofi stock in a transaction on Monday, August 2nd. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $1,000,005.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.00% of the company’s stock.
Sanofi Company Profile
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities.
Recommended Story: Basic Economics creates winners and losers
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.